Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions.

ABSTRACT: Drug-drug interactions (DDI) potentially occurring between medications used in the course of COVID-19 infection and medications prescribed for the management of underlying comorbidities may cause adverse drug reactions (ADRs) contributing to worsening of the clinical outcome in affected patients. First, we conducted a meta-analysis to determine comorbidities observed in the course of COVID-19 disease associated with an increased risk of worsened clinical outcome from 24 published studies. In addition, the potential risk of DDI between medications used in the course of COVID-19 treatment in these studies and those for the management of observed comorbidities was evaluated for possible worsening of the clinical outcome. Our meta-analysis revealed an implication cardiometabolic syndrome (e.g.

SUBMITTER: Awortwe C 

PROVIDER: S-EPMC7550259 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature